BioWorld

April 1, 2008

Tekmira and Provita Merge to Form RNAi Powerhouse

Canadian firms Tekmira Pharmaceuticals Corp. and Protiva Biotherapeutics Inc. are merging to become a stronger international player in the RNA interference therapeutics space. (BioWorld Today) Read More

Merck, Schering Knocked by Vytorin Data, Physician Panel

Even in Hindsight, No Problems with Co-Stimulation in Rodents

$10M Deal: Acusphere Licenses HDDS, Compound to Cephalon

Transave Garners $35M to Aid Pipeline Push in Lung Diseases

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...